PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of bmcpsycBioMed Centralsearchsubmit a manuscriptregisterthis articleBMC Psychiatry
 
BMC Psychiatry. 2011; 11: 173.
Published online Nov 1, 2011. doi:  10.1186/1471-244X-11-173
PMCID: PMC3305894
Prevalence of metabolic syndrome in patients with schizophrenia, and metabolic changes after 3 months of treatment with antipsychotics - results from a German observational study
Susanne Kraemer,corresponding author1 Anette Minarzyk,1 Thomas Forst,2 Daniel Kopf,3 and Hans-Peter Hundemer1
1Lilly Deutschland GmbH, Medical Department, 61352 Bad Homburg, Werner -Reimers-Str. 2-4, Germany
2Institute for Clinical Research IKFE, 55116 Mainz, Parcusstr. 8, Germany
3Kath. Marienkrankenhaus GmbH, Geriatrics Clinic, 22087 Hamburg, Alfredstr.9, Germany
corresponding authorCorresponding author.
Susanne Kraemer: kraemer_susanne/at/lilly.com; Anette Minarzyk: minarzykan/at/lilly.com; Thomas Forst: thomasf/at/ikfe.de; Daniel Kopf: dkopf.geriatrie/at/marienkrankenhaus.org; Hans-Peter Hundemer: hundemer_hans-peter/at/lilly.com
Received April 28, 2011; Accepted November 1, 2011.
Abstract
Background
This observational study explored the prevalence of metabolic syndrome (MetS) in adult in- and outpatients with untreated or treated schizophrenia at baseline, and month-3 after initiation or switch of antipsychotic treatment.
Methods
MetS-prevalence (AHA/NHLB-definition) was assessed and Clopper-Pearson 95% confidence intervals (CIs) were calculated. Factors associated with MetS were explored through univariate and multivariate logistic regressions (both visits).
Results
MetS-prevalence was 44.3% (CI 39.8;48.9) at baseline and 49.6% (CI 45.0;54.2) at month-3. Previously unmedicated patients showed the lowest baseline MetS-prevalence (24.7%, CI 18.3;32.1). MetS-prevalence was not significantly different, regardless if patients previously received typical or atypical antipsychotics. Increased MetS-risk was associated with somatic comorbidity and non-smoking at both visits, and with non-psychiatric co-medication, male sex, and increased C-reactive protein at month-3.
Conclusions
At baseline, MetS was most prevalent in patients with previous antipsychotic medication. Limited metabolic changes were observed 3 months after switch/initiation of antipsychotic therapy.
Trial Registration Number
ClinicalTrials.gov Identifier: n.a.
Articles from BMC Psychiatry are provided here courtesy of
BioMed Central